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Background: A high level of resistance in Neisseria gonorrhoeae has developed against penicillins, sulphonamides,
tetracyclines and quinolones, and recent surveillance data have shown a gradual reduction in sensitivity to current
first-line agents with an upward drift in the minimum inhibitory concentration of ceftriaxone. Laboratory sensitivity
testing suggests that gentamicin, an aminoglycoside, may be an effective treatment option for gonorrhoea
infection when used as a single intramuscular dose.
Methods: A search of electronic reference databases and grey literature was used to identify randomised trials and
well-conducted prospective studies with concurrent controls evaluating single-dose gentamicin against placebo or
a comparator regimen in the treatment of uncomplicated gonorrhoea infection in men and women aged 16 years
and over. The primary outcome was microbiological cure of N. gonorrhoeae.
Results: Eight hundred and thirty-nine studies were identified, of which five (1,063 total participants) were included.
All five studies administered single-dose gentamicin via intramuscular injection to men with uncomplicated gonococcal
urethritis. Three studies were randomised trials, one was quasi-randomised and one was non-randomised but included
a comparator arm. Comparator antibiotics included an alternative aminoglycoside or antibiotic used in the syndromic
management of male urethritis. Methodology was poorly described in all five included studies. The high risk of bias
within studies and clinical heterogeneity between studies meant that it was inappropriate to pool data for
meta-analysis. Cure rates of 62% to 98% were reported with gentamicin treatment. The relative risk of cure
was comparable between gentamicin and comparator antibiotics.
Conclusions: The studies identified provide insufficient data to support or refute the efficacy and safety of
single-dose intramuscular gentamicin in the treatment of uncomplicated gonorrhoea infection. Additional randomised
trials to evaluate gentamicin for this indication are therefore required.
Systematic review registration: PROSPERO CRD42012002490
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Gonorrhoea, caused by Neisseria gonorrhoeae, is the
second most common bacterial sexually transmitted
infection in the UK. The number of gonorrhoea diagno-
ses continues to rise with latest data indicating a 52%
increase in England from 16,835 to 25,525 infections
between 2010 and 2012 [1]. The highest rates of infec-
tion are found in residents of urban areas, and infection
is concentrated in core groups such as young people and* Correspondence: emma.hathorn@nhs.net
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unless otherwise stated.men who have sex with men (MSM). Of male diagnoses
in 2012, 42% were reported in MSM and 55% of hetero-
sexual diagnoses were in those aged 15 to 24 years [1]. A
number of factors, in addition to continuing levels of
unsafe sexual behaviour, may have contributed to the
observed increase in diagnosis of gonorrhoea including
the introduction of highly sensitive nucleic acid amplifi-
cation tests (NAATs), the introduction of self-testing
including extra-genital sites (pharyngeal and rectal sites
in MSM), an increase in sexual health screening follow-
ing the roll-out of the National Chlamydia Screening
Programme, and improvements in reporting and sur-
veillance. However, the rise in incident infection reportedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Organization (WHO) estimates gonorrhoea to represent
106.1 million of the 498.9 million new cases of curable
sexually transmitted infections (syphilis, chlamydia, gonor-
rhoea and trichomoniasis) worldwide [2].
N. gonorrhoeae are intracellular gram-negative bacteria
transmitted via sexual contact. They primarily infect the
mucous membranes of the urethra, endocervix, rectum,
pharynx and conjunctiva. Infection of the genital tract
causes local inflammation that can result in dysuria, dis-
charge, genital discomfort and pain. Infection in women
may spread to the fallopian tubes and ovaries causing
pelvic inflammatory disease (PID). Complications include
infertility, chronic pelvic pain and ectopic pregnancy and
can result in considerable physical and emotional morbid-
ity in addition to a significant financial burden on health-
care services [3,4]. An estimate of the average lifetime
costs for women who develop complications is $6,350
for chronic pelvic pain, $6,840 for ectopic pregnancy and
$1,270 for infertility [4].
Gonorrhoea has consistently been identified as a risk
factor for incident HIV infection in both heterosexual
and MSM populations [5-7]. This is thought to result
from increased HIV viral shedding in genital secretions
[8,9] and from an increased concentration of target cells
for HIV in the locally inflamed mucosa found in individ-
uals with gonorrhoea [10]. Ensuring effective gonorrhoea
testing and treatment is therefore important to both re-
duce the global incidence of curable sexually transmitted
infections and control the spread of HIV.
Testing guidance advocates the use of NAATs to detect
gonorrhoea [11-14]. These tests benefit from high sensi-
tivity and specificity, quick turnaround times, ability to
use non-invasive specimens from patients and permitting
dual screening for chlamydia and gonorrhoea at extra-
genital sites. However, to allow antibiotic susceptibility
testing, a sample for culture is also required. In vitro
susceptibility testing is used to guide individual patient
management in addition to providing data for surveillance
programmes. Antibiotic resistance in N. gonorrhoeae is a
continuing problem, and surveillance of antibiotic resist-
ance with a change in empirical treatment when resistance
occurs in >5% of isolates is recommended [15]. This is of
particular importance in resource-limited settings where
testing for N. gonorrhoeae is difficult and individuals are
typically treated using syndrome-based algorithms.
A high level of resistance in N. gonorrhoeae has
developed against penicillins, sulphonamides, tetracy-
clines and fluoroquinolones, which are now no longer
recommended for use. Current guidelines recommend
a single dose of intramuscular ceftriaxone with or with-
out the addition of a single oral dose of azithromycin
for the treatment of uncomplicated gonorrhoea infec-
tion [12,14,16,17]. The European Centre for DiseasePrevention and Control (ECDC) has proposed a working
case definition for confirmed treatment failure that in-
cludes both clinical and laboratory criteria [18]. The
precise resistance breakpoint for cephalosporin antibiotics
is unknown, but surveillance data from the gonococcal
isolate surveillance projects in both the UK and US
have reported an upward drift in the mean inhibitory
concentration (MIC) of ceftriaxone (UK: 13% with MIC
over 0.03 mg/l in 2010 cf. 1% in 2007 [19]; US: 0.05% with
MIC over 0.125 mcg/ml in 2006 cf. 0.5% in 2010 [20]).
Clinical failure of cephalosporins has now been reported
in Japan and Europe [21-23].
The mechanism of resistance to cephalosporin antibi-
otics is not fully understood. Plasmid-mediated resistance
has not been observed, but a number of chromosomal
mechanisms, including the presence of mosaic penA genes
and mutations in penA, penB, mtrR promoter and mtrR
genes, have been reported. Mosaicism of the penA gene
that encodes penicillin-binding protein 2 (PBP2) is thought
to be the predominant mechanism causing cephalosporin
resistance. Penicillin-binding proteins are involved in the
synthesis of peptidoglycan, a major component of bacterial
cell walls. Mosaic sequences of PBP2, resulting from re-
combination events involving penA gene sequences from
other Neisseria species, have been identified in clinical iso-
lates that demonstrate reduced susceptibility to cefixime
and ceftriaxone [24-26]. Options to treat gonorrhoea if
cephalosporins become ineffective are severely limited.
Gentamicin, an aminoglycoside antibiotic, is known to
be clinically effective in the treatment of gram-negative
infections, exerting both a bacteriostatic and bactericidal
effect. It is an inexpensive antibiotic and has been used
successfully to treat genital gonorrhoea infections in
resource-limited settings. Studies in Malawi have shown
high susceptibility of gonococcal isolates to gentamicin
in vivo and clinical cure rates of approximately 95% when
used in combination with doxycycline [27,28]. Whilst it is
not included in current UK or European gonorrhoea treat-
ment guidelines, an evaluation of gentamicin susceptibility
of gonorrhoea isolates across 17 European countries was
performed in 2009 in response to the emergence of
decreased susceptibility to third-generation, extended-
spectrum cephalosporins. The majority of MICs for geni-
tal and rectal isolates fell within a narrow range: 95% of
isolates within 4–8 mg/l and 79% of isolates demonstrat-
ing an MIC of 8 mg/l [29]. Cephalosporin-resistant gono-
cocci are unlikely to exhibit cross-resistance to gentamicin
given its bacteriostatic action via the bacterial ribosome in
contrast to the action of cephalosporins on bacterial cell
wall synthesis. Administration of gentamicin is limited to
either the intravenous or intramuscular routes, and the
optimal dose for uncomplicated genital infections is not
known. However, a single intramuscular injection of anti-
biotic lends itself to outpatient management and may
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with extended high trough drug concentrations.
In view of concerns about decreasing sensitivity of N.
gonorrhoeae to current first-line agents, there is a clear
need to identify treatment options. This systematic re-
view assesses the clinical effectiveness and safety of gen-
tamicin for the treatment of N. gonorrhoeae.
Methods
The review protocol was registered with PROSPERO
(CRD42012002490) [30].
Criteria for considering studies for the review
Types of study
Randomised controlled trials, quasi-randomised trials
and prospective studies with concurrent controls and
consistent treatment assignment were eligible for inclu-
sion. Studies with historical controls, before and after
studies, case series and case reports were excluded.
Types of participants
Studies recruiting men and women aged 16 years or over
receiving their first antibiotics as an inpatient or out-
patient for a microbiological diagnosis of gonorrhoea at
any anatomical site were included. Gonorrhoea was di-
agnosed by microscopy, culture or nucleic acid amplifi-
cation tests.
Types of intervention
Studies in which gentamicin was given at any single dose
intramuscularly or intravenously were eligible for inclu-
sion. To enable assessment of gentamicin efficacy, stud-
ies in which gentamicin was given as part of a combined
antibiotic regimen were excluded. Comparators included
no treatment, placebo or any alternative antibiotic given
either orally or parenterally.
Types of outcome
Primary outcome The primary outcome is micro-
biological cure of N. gonorrhoeae (negative microscopy,
culture or nucleic acid amplification test).
Secondary outcomes The secondary outcomes are the
following:
 Clinical resolution of symptoms (dysuria, genital
discharge, genital pain or abdominal pain).
 Need for additional antibiotic therapy.
 Adverse events (rash, allergy, injection site
discomfort, renal dysfunction, hearing loss,
vestibular dysfunction, other reported adverse events
attributed to antibiotic).
 Hospital attendance (admission to hospital,
unscheduled clinic attendance).Search strategy for identification of studies
Electronic searches
A search strategy was developed and used to identify rele-
vant studies (Additional file 1). Databases were searched
on 11th May 2012 and 27th July 2012 and updated on
2nd June 2014 as follows: MEDLINE from PubMed 1950
to present, Embase 1980 to present, CINAHL 1981 to
present, CAB Abstracts, EThOS and the Cochrane Cen-
tral Register of Controlled Trials. Searches were repeated
of www.clinicaltrials.gov and www.who.int/trialsearch to
identify ongoing trials. Papers published in peer-reviewed
journals, theses, conference abstracts and reports were
included. No language restriction was placed on the
search strategy.
Searching other resources
Searches were repeated in grey literature to identify any
unpublished and ongoing research (Additional file 1).
References from included studies were reviewed for fur-
ther relevant studies.
Data collection and analysis
Study selection
Two reviewers (DD and EH) independently screened titles
and abstracts against the inclusion criteria to identify eli-
gible citations. Disagreements were resolved by discussion.
Full-text copies were obtained if insufficient information
was available and of all studies meeting inclusion criteria.
Data extraction
A standardised data extraction form was developed and
utilised. Data were independently extracted from the stud-
ies, and discrepancies were resolved by discussion and
consultation with a third reviewer if necessary.
Assessment of risk of bias
Risk of bias in studies was assessed using the risk of bias
tool described in the Cochrane Handbook for Systematic
Reviews of Interventions [31]. A bias judgement (low
risk of bias, high risk of bias or unclear risk of bias) was
allocated to each of six domains (sequence generation,
allocation of sequence concealment, blinding, incom-
plete outcome data, selective reporting bias and other
bias) within the tool. The tool was developed for assess-
ment of randomised trials, and the Good Research for
Comparative Effectiveness (GRACE) checklist, which
has been utilised to rate the quality of observational
studies of comparative effectiveness, was used to assess
non-randomised studies included for data analysis [32].
Data synthesis
Characteristics, main findings and risk of bias assess-
ment were tabulated for each study. Levels of attrition
were noted for included studies. If data were adequate
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as a summary risk ratio with 95% confidence intervals,
on an intention-to-treat basis.
Reviewing the studies identified a high level of clinical
heterogeneity. The dose of gentamicin varied from 160
to 280 mg, and the primary assessment of cure was
based on symptoms, microscopy and culture or was not
reported. The definition and assessment of risk of re-
infection was not reported in some studies [33-35], and
those with potential re-exposure were excluded in one
study [36]. Meta-analysis was considered to be inappro-
priate due to these methodological differences and the
results summarised in a tabular format.
Results
Eight hundred and thirty-nine studies were identified by
the search strategy (Figure 1). Two reviewers independ-
ently screened all titles and available abstracts. Nineteen
studies were discussed due to disagreement, of which 17
were excluded, as they did not meet pre-specified inclu-
sion criteria. Seventeen full-text articles were retrieved
and 12 were excluded after further review.
Five studies with a total of 1,063 participants were in-
cluded in the review: three randomised trials [28,33,34],
one quasi-randomised trial [36] and one non-randomised
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Figure 1 Review profile.Description of studies
Table 1 summarises the characteristics of the included
studies. All five studies included men with uncompli-
cated gonococcal urethritis diagnosed by culture [34],
identification of gram-negative diplococci on urethral
smear [36] or a combination of Gram-stained urethral
smear and culture [28,34,36]. Five hundred and twenty-
nine men received intramuscular gentamicin in a single
dose—160 mg (n = 20), 240 mg (n = 207) or 280 mg (n =
302). No study compared gentamicin to placebo and
comparator antibiotics included an alternative aminogly-
coside (kanamycin and spectinomycin) or antibiotic used
in the syndromic management of male urethritis.
Assessment of risk of bias
The included studies were assessed for risk of bias using
either the Cochrane risk of bias tool (randomised stud-
ies) or the GRACE checklist (observational studies).
Study methodology was poorly reported, so that consist-
ently assessing methodological quality and risk of bias
in each individual study was difficult. Insufficient de-
tail was often included in the publication to distinguish
accurately what was done in contrast to what was re-
ported. As such, risk of bias within and across individual
studies was unclear or judged by reviewers to be high
(Additional file 2).uplicates removed
rcles excluded:
 comparator arm (n=5)
ntamicin given in combinaon (n=1)
oratory based in vitro studies (n=2)
able to obtain full text (n=4)
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Table 1 Characteristics of included studies
















injection (n = 302)
Single-dose kanamycin 2 g
intramuscular injection (n= 113)
Cure All patients advised to abstain
from sexual activity for 2 weeks
after therapy.
Patients in whom N. gonorrhoea
persisted or re-appeared (as
determined by a positive result of
a smear or culture) in the absence
of sexual activity during the
follow-up period were considered
to be treatment failure
Patients excluded if reported sexual
activity during 2 weeks follow-up
period with or without persistent
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injection (n = 30)
Co-trimoxazole (Bactrim,
Roche) 8 tablets daily divided
into 2 doses for 2 days (n= 30).
Trimethoprim-sulphametrol
(Lidaprim, Ciba) 8 tablets
divided into 2 doses for 2 days
(n= 30)
Cure One case of re-infection reported
in which there was a history of
re-exposure.
Cases with negative smears plus
resolution of discharge on day 7
were considered cured
Safe sex advice and assessment














injection (n = 20)
Single-dose spectinomycin
2 g intramuscular injection
(n = 20)
Cure Safe sex advice, definition and
assessment of re-infection not
describedPatients in whom culture on
days 3, 7 and 14 post treatment

















injection (n = 137)
Single-dose kanamycin 2 g
intramuscular injection
(n = 137)
Cure All patients advised to avoid
sexual intercourse during the
period of treatment. Definition
and assessment of re-infection
not described
Cases with negative Gram stain
and bacteriological test
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injection (n = 40)
Amoxicillin 3 gm, probenecid
1 gm, and clavulanate
125 mg by mouth once
(n = 60)
To determine the relative
contribution of gonorrhoea and
chlamydia to urethritis in Malawi
Safe sex advice not described
Amoxicillin 3 gm, probenecid
1 gm, and clavulanate
125 mg, by mouth once and
doxycycline 100 mg BD for
7 days (n = 56)
To evaluate the effectiveness of
five antibiotic therapies for
urethritis
6/48 (12.5%) patients with
persistent gonococcal infection
at follow-up reported having sex
between initial and follow-up
visits compared to 21 of 249
(8.4%) men for whom gonococcal
infection was not detected at
follow-up (p = 0.4)
Ciprofloxacin 250 mg by
mouth once (n = 59)
Cure not defined. An assessment
of symptoms and signs, urethral
Gram stain and culture were




1,600 mg) by mouth for
2 days (n = 29)




















Table 2 Outcome data of included studies
Outcome Hira et al. [36] Iskandar et al. [33] Pareek and Chowdhury [35] Yoon et al. [34] Lule et al. [28]
Cure Gentamicin: 98% (216/220) Gentamicin: 27/30 (90%) Gentamicin: 19/20 (95%) Gentamicin: 78/125 (62.4%) Gentamicin: 38/40 (95%)
Kanamycin: 95% (85/89) Co-trimoxazole: 29/30 (96.6%) Spectinomycin: 16/20 (80%) Kanamycin: 86/126 (68.3%) Ciprofloxacin: 55/59 (93%)
Lidaprim: 29/30 (96.6%) 23 patients did not
attend follow-up and were
excluded
APC: 40/60 (67%)
Adjusted to include only
those attending on day 7:
APC-D: 52/56 (93%)
Gentamicin: 19/22 (86.4%) Co-trimoxazole: 14/29 (48%)
Bactrim: 15/16 (93.7%)
Lidaprim: 20/21(95.2%)
Need for additional treatment No data No data No data No data No data
Adverse event ‘No serious toxicity or other adverse
reactions were noticed in either group
of men. Serum creatinine values were
normal in the 52 patients given
gentamicin and the 28 kanamycin
whose blood samples were tested’
‘No adverse side effects
were observed in any
of the patients’
‘There were no obvious side
effects with either of these
drugs. The blood urea and
creatinine values remained
within normal limits’
‘There was no side effect
of using kanamycin and
gentamicin’
No data
Hospital attendance No data No data No data No data No data






























Risk Ratio (log 10 scale)
Favours gentamicinFavours comparator
Figure 2 Efficacy of gentamicin. The probability of cure following treatment with gentamicin compared to cure with a comparator antibiotic. The
probability of cure was comparable between gentamicin and comparator antibiotics. TMPSMX trimethoprim/sulphamethoxazole, APC amoxicillin,
probenecid and clavunate, APC-D amoxicillin, probenecid, clavunate and doxycycline. Risk ratios: Lule (TMPSMX) 1.9679 (95% CI 1.3412-2.8873); Lule (APC-D)
1.0231 (95%CI 0.924201.1325); Lule (APC) 1.4250 (95% CI 1.1754-1.7275); Lule (ciprofloxacin) 1.0191 (95% CI 0.9231-1.1251); Pareek (specinomycin) 1.1875
(95% CI 0.9331-1.5113); Iskander (Bactrim) 0.9310 (95% CI 0.8122-1.0672); Iskander (Lidaprim) 0.9310 (95% CI 0.8122-1.0672); Yoon (kanamycin) 0.9142
(95% CI 0.7630-1.0954); Hira (kanamycin) 1.0280 (95% CI 0.979301.0791).
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All five studies reported cure, as defined in Table 1, as a
primary outcome (Table 2). Fixed effects meta-analysis
was not performed for any of the defined outcomes due
to the high level of clinical heterogeneity between stud-
ies and the high risk of bias within individual studies
(Additional file 2). Whilst cure, presented as a percentage
rate, was reported in each of the included studies, they dif-
fered significantly in definition of cure (clinical cure or
negative microscopy and/or culture), timing of cure and
their assessment of re-infection (Additional file 3).
Figure 2 summarises the efficacy of gentamicin in the
treatment of uncomplicated gonorrhoea infection. The
probability of cure was comparable between gentamicin
and comparator antibiotics.
Discussion
Our systematic review found insufficient data to support
or refute the role of gentamicin in the treatment of gonor-
rhoea infections. Five studies of single-dose intramuscular
gentamicin for the treatment of uncomplicated gonococcal
urethritis in men met inclusion criteria and reported cure
rates of 62% to 98%. The probability of cure was compar-
able between gentamicin and comparator antibiotics.
A separate systematic review assessing the effectiveness of
gentamicin for uncomplicated urogenital gonorrhoea infec-
tion has recently been published [37] and reported a pooled
percentage with negative culture after single-dose gentami-
cin of 91.5% (95% CI 88% to 94%). It included three studies
of which only two met our inclusion criteria due to meth-
odological differences [36]. Firstly, Dowell and Kirkcaldy in-
cluded studies with historical controls and single-arm case
series. Secondly, they included studies in which gentamicinwas given as part of a treatment regimen in combination
with other antibiotics. Thirdly, their definition of gonorrhoea
was limited to participants with uncomplicated urogenital
infection and diagnosis was restricted to urethral or cervical
culture at the time of treatment and follow-up.
Our data supports the conclusion that gentamicin may
not achieve the 95% cure rate recommended by the World
Health Organization for empirical therapy. However, the
risk of bias within available studies limits any firm conclu-
sions being drawn and a potential role for gentamicin as
an alternative or adjunctive agent remains and merits
evaluation in randomised trials. Preliminary data from an
American study examining the effectiveness of gentamicin
with azithromycin recently suggested high efficacy (202/
202 negative culture at 10–17 days post treatment) but
poor tolerability of this regimen (27.7% reporting nausea
and 47% any gastrointestinal disturbance) [38]. Also, this
study did not determine the efficacy of the individual anti-
biotics, or efficacy of gentamicin for extra-genital infec-
tions, and further randomised control trials incorporating
currently recommended antibiotic regimens, comparing
different gentamicin doses and correlating in vitro genta-
micin susceptibilities to clinical response are needed.
A comprehensive review of the literature was per-
formed with all relevant identified articles obtained and
translated. Few studies met the inclusion criteria with
limited numbers of patients receiving single-dose intra-
muscular gentamicin. The five studies included for data
extraction were performed in Malawi, Zambia, Egypt,
Korea and Saudi Arabia, and their findings may not be ap-
plicable to other settings where first-line treatment regi-
mens and gentamicin susceptibility may differ. No studies
of genital infection in women or non-genital gonorrhoea
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findings cannot be extrapolated to these groups.
Quality of included studies
Two of the identified studies were very small with 20 [35]
and 30 [33] patients receiving gentamicin. The comparator
antibiotic varied across the included studies, and all were
suboptimal when compared to current UK management
guidelines. Two studies were described as randomised con-
trol trials, but none adequately described their method of
generating a random allocation sequence, method of con-
cealment or blinding to the allocation schedule. In addition,
differences in definition of gonococcal infection, gentamicin
dosing, comparator antibiotic, evaluation of re-infection
and definition and timing of cure meant that it was
inappropriate to pool data for meta-analysis.
Conclusions
Based on current evidence, there are insufficient data to
support or reject a recommendation for inclusion of single-
dose gentamicin as a first-line agent in the treatment of un-
complicated gonorrhoea infection. Further high-quality
RCTs incorporating currently recommended antibiotic regi-
mens with laboratory measurement of gentamicin MIC are
needed to inform a change in clinical practice.
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